Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086

Adamus WS, Heuer H, Meade CJ, Brecht HM (1989) Safety, tolerability, and pharmacologic activity of multiple doses of new platelet activating factor antagonist WEB 2086 in human subjects. Clin Pharmacol Ther 45: 270–276

Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P (2001) Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann NY Acad Sci 943: 296–315

Alessandri G, Raju KS, Gullino PM (1986) Interaction of gangliosides with fibronectin in the mobilization of capillary endothelium. Possible influence on the growth of metastasis. Invasion Metastasis 6: 145–165

Brunton VG, Workman P (1993) In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434. Br J Cancer 67: 989–995

Bussolati B, Biancone L, Cassoni P, Russo S, Rola-Pleszczynski M, Montrucchio G, Camussi G (2000) PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol 157: 1713–1725

Carmel I, Fares FA, Leschiner S, Scherübl H, Weisinger G, Gavish M (1999) Peripheral-type benzodiazepine receptors in the regulation of proliferation of MCF-7 human breast carcinoma cell line. Biochem Pharmacol 58: 273–278

Casals-Stenzel J, Muacevic G, Weber K (1987) Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J Pharmacol Exp Ther 241: 974–981

Cellai C, Laurenzana A, Vannucchi AM, Della Malva N, Bianchi L, Paoletti F (2002) Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells. FASEB J 16: 733–735

Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP (2005) Crucial role of p53-dependent cellular senescence in suppression of PTEN-deficient tumorigenesis. Nature 436: 725–730

Constantinou AI, Krygier AE, Mehta RR (1998) Genistein induces maturation of cultured human breast cancer cells and prevents tumor growth in nude mice. Am J Clin Nutr 68: 1426S–1430S

Druker BJ (2002) STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 8: S14–S18

Giers G, Janzarik H, Kempe ER, Mueller-Eckhardt C (1990) Failure of the platelet-activating-factor antagonist WEB 2086 BS for treatment of chronic autoimmune thrombocytopenia. Blut 61: 21–24

Graziani G, Tentori L, Portarena I, Vergati M, Navarra P (2003) Valproic acid increases the stimulatory effect of oestrogens on proliferation of human endometrial adenocarcinoma cells. Endocrinology 144: 2822–2828

Guilbaud NF, Gas N, Dupont MA, Valette A (1990) Effects of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells. J Cell Physiol 145: 162–172

Hardwick M, Rone J, Han J, Haddad BR, Papadopoulos V (2001) Peripheral-type benzodiazepine receptor levels correlate with the ability of human breast cancer MDA-MB-231 cell line to grow in SCID mice. Int J Cancer 94: 322–327

Ishii S, Shimizu T (2000) Platelet-activatig factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res 39: 41–82

Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ, Lee JS (2004) The histone deacetylase inhibitor trichostatin A sensitizes oestrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 23: 1724–1736

Laurenzana A, Cellai C, Vannucchi AM, Pancrazzi A, Romanelli MN, Paoletti F (2005) WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential. Leukemia 19: 390–395

Lyons AB, Hasbold J, Hodgkin PD (2001) Flow cytometric analysis of cell division history using dilution of carboxyfluorescein diacetate succinimidyl ester, a stably integrated fluorescent probe. Methods Cell Biol 63: 375–398

Lohmann HF, Adamus WS, Meade CJ (1988) Idiopathic thrombocytopenia treated with Paf-acether antagonist WEB 2086. Lancet 2: 1147

Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61: 8492–8497

Pandolfi PP (2004) Breast cancer – loss of PTEN predicts resistance to treatment. N Engl J Med 351: 2337–2338

Paoletti F, Mocali A, Cellai C, Caporale R, Vannucchi AM (1996) Megakaryocyte-like increase in ploidy of Friend's erythroleukemia cells induced to endoreplication by colcemid. Exp Hematol 24: 1441–1448

Rochefort H, Garcia M, Glondu M, Laurent V, Liaudet E, Rey JM, Roger P (2000) Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 291: 157–170

Sommer S, Fuqua SA (2001) Estrogen receptor and breast cancer. Semin Cancer Biol 11: 339–352

Svetlov SI, Barton JM, Olson MS (1996) The specific binding of the platelet-activating factor (PAF) receptor antagonist WEB 2086 and the benzodiazepine flunitrazepam to rat hepatocytes. Life Sci 58: PL81–PL86

Wang Q, Lee D, Sysounthone V, Chandraratna RAS, Christakos S, Korah R, Wieder R (2001) 1,25-dihydroxyvitamin D3 and retinoic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res Treat 67: 157–168

Warrell Jr RP, Frankel SR, Miller Jr WH, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324: 1385–1393

Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE (2000) Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60: 6890–6894